Author

M. N. Tea

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Assay:flow cytometry· 2 Organism:human· 2 Assay:imaging· 2 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Assay:proteomics· 1

Frequent Co-Authors

L. M. Ebert· 2 shared M. P. Brown· 2 shared S. M. Pitson· 2 shared T. Gargett· 2 shared W. Yu· 2 shared B. L. Gliddon· 1 shared D. S. Ziegler· 1 shared E. C. F. Yeo· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

L. M. Ebert

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Endogenous bystander killing mechanisms enhance the activity of novel FAP-CAR-T cells against glioblastoma

W. Yu, N. T. Truong, R. Polara, T. Gargett, M. N. Tea, S. M. Pitson, L. M. Ebert, M. P. Brown

This study shows FAP-CAR-T cells effectively kill glioblastoma cells through bystander mechanisms, even when only some cells express FAP, and demonstrate therapeutic efficacy in vivo.

bioRxiv · Feb 21, 2023 · PreprintImmunology

GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma

T. Gargett, L. M. Ebert, N. T. H. Truong, P. M. Kollis, K. Sedivakova, W. Yu, E. C. F. Yeo, N. L. Wittwer, B. L. Gliddon, M. N. Tea, R. Ormsby, J. Nowicki, S. Poonnoose, O. Vittorio, D. S. Ziegler, , M. P. Brown

This study demonstrates that GD2-targeting CAR-T cells, enhanced with IL-15 transgene expression, effectively control glioblastoma growth in a preclinical model and are clinically feasible.

bioRxiv · May 1, 2022Immunology